Skip to content
World clockEU--:--UK--:--USA--:--CN--:--PLDEFRIT中文EN

portal about AI and technologyevents · analysis · interviews · technical background

Search
LIVE
›

Isomorphic Labs in talks to raise about $5bn at a $50bn valuation

Isomorphic Labs is in talks to raise about $5bn at a valuation of about $50bn, Bloomberg reported on Wednesday. The Alphabet spinout has not put an AI-designed drug into human trials.

ScienceNewsSofia MarchettiPublished: 9 November 20264 min readSources 28
Isomorphic Labs in talks to raise about $5bn at a $50bn valuation

Talks at $50bn

The financing has not closed and terms could change. The investors expected to back the round were not named. Bloomberg's October reporting had Isomorphic Labs in early talks at a valuation of $40bn or more, and as high as $50bn. The new figure sits at the top of that range. The October story did not specify how much the company wanted to raise; the new report puts it at about $5bn. Isomorphic Labs did not disclose a valuation for its May round, so there is no public benchmark against which to measure the jump. If the $50bn figure includes the new money, the $5bn would be roughly 10% of the company; if it does not, roughly 9%.

Still before the clinic

Max Jaderberg, the company's president, said on Monday at Bloomberg Tech in London that its drug work was still in preclinical stages. He described Isomorphic Labs as being in its 'first innings'. Demis Hassabis, the chief executive, said in January that first clinical trials were expected by the end of 2026, a slip from an earlier target of the end of 2025. No Isomorphic-designed drug has entered human testing.

The $50bn figure is about 13 times the $3.8bn valuation Chai Discovery reached with a $400m round in July. Basecamp Research raised $140m at an $800m valuation in September, which on the same comparison would leave Isomorphic Labs more than 60 times its size. Grand View Research forecasts the AI drug discovery market will be worth $13.8bn by 2033, up from $2.3bn in 2025.

What the new money would follow

Isomorphic Labs raised $600m in March 2025 in its first external round. The round was led by Thrive Capital. It announced a $2.1bn Series B on 12 May 2026, again led by Thrive Capital. Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund took part, according to the company's announcement. That round took total external funding to about $2.7bn; a $5bn raise would lift the figure to about $7.7bn in under two years. BioSpace reported that the Series B was the second largest biotech round of all time, behind Altos Labs' $3bn in 2022. Isomorphic Labs had over 350 staff across London, Cambridge, Massachusetts and Lausanne as of May. The company said the money would fund continued development of IsoDDE and push its pipeline of therapeutic programmes towards the clinic.

Pharma deals behind the pitch

Eli Lilly signed in January 2024 with $45m upfront and up to $1.7bn in milestone payments, while Novartis paid $37.5m upfront with up to $1.2bn in contingent payments. Johnson & Johnson joined as a partner in January 2026 on terms the company has not disclosed. Tech Funding News reported that milestone payments are contingent on achieving development milestones.

What happens next

Jaderberg made a broader claim at the same event. "Our hypothesis has been proven," he said. "Our preclinical data is helping us to gear up for clinical developments."

SiliconANGLE reported that Isomorphic Labs said in February its engine was more than 50% better at finding binding pockets than the closest competing tool. The company also said the engine modelled interactions between binding pockets and antibodies about 2.3 times better than AlphaFold. Tech Funding News noted that a trial would not prove a drug works, but would show the company can get a candidate into human testing. If another delay follows the one in 2025, the valuation would rest on partnerships and technical claims that have not been validated, that outlet reported.

Comments 0

Sources

28
  1. 01Isomorphic Labs in talks to raise $5bn at a $50bn valuation, Bloomberg reportsEN
  2. 02Report: Isomorphic Labs in talks to raise $5B at $50B valuationEN
  3. 03Isomorphic Labs in talks for $5B round at $50B valuationEN
  4. 04Isomorphic Labs Eyes $50B Valuation in $5B Funding RoundEN
  5. 05Alphabet spinoff Isomorphic Labs reportedly raising funding at up to $50B valuationEN
  6. 06Alphabet's Isomorphic Labs seeks valuation of at least $40 billion in new funding roundEN
  7. 07Isomorphic Labs seeks funding at a valuation of at least $40 billionEN
  8. 08Google-backed Isomorphic Labs delays clinical trial timelineEN
  9. 09Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engineEN
  10. 10Wilson Sonsini Advises Isomorphic Labs on $2.1 Billion Series B Investment RoundEN
  11. 11Isomorphic Labs lands $1.2bn fund to advance AI drug design modelEN
  12. 12AI-fueled Isomorphic bags $2.1B, the second largest biotech round everEN
  13. 13Isomorphic Labs Lands $2.1 Billion Series B for AI Drug Design Engine – - The Healthcare Technology Report.EN
  14. 14Inside Big Pharma and VC’s big bet on AI: You wouldn’t ‘want to fly an airplane designed by hand, but all of our drugs are designed like that’ - FortuneEN
  15. 15Isomorphic Labs Raises $2.1B for AI Drug Discovery - VentureburnEN
  16. 16Sovereign AI fund supports Hassabis startup, IsomorphicEN
  17. 17STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye conditionEN
  18. 18STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and moreEN
  19. 19STAT+: Why the latest heart drug failures should make us all more skeptical of AI hypeEN
  20. 20Designing Smarter Security and Portable Camera SystemsEN
  21. 21STAT+: BIO joins the legal fight against Medicare pilot that ties drug prices to peer countriesEN
  22. 22STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategyEN
  23. 23Nio Firefly wins 2026 Red Dot Award for smart cockpit designEN
  24. 24#AHA26: The similar, surprising Novo and Novartis heart drug failures spelled outEN
  25. 25An anti-aging drug may help protect the brain before Alzheimer's symptoms beginEN
  26. 26Why Integrated Gate Drive Regulation Matters For High Reliability Space GaN DesignsEN
  27. 27Scientists trick cancer cells into making the drugs that kill themEN
  28. 28Scientists discover new Alzheimer’s drug that repairs DNA damage and reduces brain inflammationEN

All figures and quotations in this text come from the sources listed below.

Content prepared by the editorial team with AI assistance.

Sofia Marchetti

Sofia Marchetti

Science and health

Sofia Marchetti covers science and health for FLASH24, working from primary literature, preprints, and agency data rather than press releases. She checks sample sizes, confidence intervals, and whether a study's numbers match its abstract before filing. She interviews researchers and clinicians directly, tracks conference calendars for embargoed results, and compares new findings with earlier trials on the same question. Outside the newsroom she works on materials physics and stargazes through a home telescope, which keeps her close to how measurement error actually behaves. She does not publish a health claim without a named source and the underlying data.

Newsroom →

Comments

0
  1. No comments yet — be the first.

Write a comment

Comments are public. We do not publish abuse, spam or advertising.